| Literature DB >> 27418883 |
I-Fan Chen1, Huey-June Wu1, Chung-Yu Chen2, Kuei-Ming Chou3, Chen-Kang Chang4.
Abstract
BACKGROUND: The decline in cognitive performance has been shown after fatiguing exercise. Branched-chain amino acids (BCAA) have been suggested to alleviate exercise-induced central fatigue. Arginine and citrulline could remove the excess NH3 accumulation accompanied with BCAA supplementation by increasing nitric oxide biosynthesis and/or urea cycle. The purpose of this study is to investigate the effect of the combined supplementation of BCAA, arginine, and citrulline on central fatigue after three simulated matches in well-trained taekwondo athletes.Entities:
Keywords: Dual task; Premotor reaction time; Taekwondo; Tryptophan
Mesh:
Substances:
Year: 2016 PMID: 27418883 PMCID: PMC4944315 DOI: 10.1186/s12970-016-0140-0
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Fig. 1Study design
Fig. 2Premotor reaction time in movement A (a), movement B (b), movement C (c), and primary task in movement D (d), and reaction time in the secondary task in movement D (e) in the taekwondo- specific reaction test battery after each simulated matches in the AA and PL trialsa. aAA: BCAA, arginine, and citrulline; PL: placebo. (a) Main effects: trial: p = .156;time: p = .001; interaction: p = .016; (b) Main effects: trial: p = .541;time: p = .019; interaction: p = .025; (c) Main effects: trial: p = .872;time: p = .037; interaction: p = .038; (d) Main effects: trial: p = .113; time: p = .152; interaction: p = .015; (e) Main effects: trial: p = .123; time: p = .036; interaction: p = .018; * p < .05, ** p < .01, *** p < .001, significantly different between the 2 trials. #Significantly different from the baseline in the PL trial (p < .05)
Motor reaction time and movement time in the taekwondo-specific reaction test battery after each simulated matches in the AA and PL trials
| Movementa | Trialb | Baseline (s) | post-M1 (s) | post-M2 (s) | post-M3 (s) | |
|---|---|---|---|---|---|---|
| Motor reaction time | A | AA | 0.295 ± 0.057 | 0.267 ± 0.055 | 0.270 ± 0.050 | 0.266 ± 0.033 |
| PL | 0.285 ± 0.040 | 0.265 ± 0.044 | 0.258 ± 0.048 | 0.270 ± 0.041 | ||
| B | AA | 0.313 ± 0.079 | 0.307 ± 0.069 | 0.269 ± 0.044 | 0.299 ± 0.064 | |
| PL | 0.314 ± 0.043 | 0.305 ± 0.054 | 0.292 ± 0.070 | 0.303 ± 0.056 | ||
| C | AA | 0.342 ± 0.066 | 0.303 ± 0.067 | 0.287 ± 0.043 | 0.307 ± 0.038 | |
| PL | 0.314 ± 0.055 | 0.305 ± 0.051 | 0.304 ± 0.051 | 0.303 ± 0.055 | ||
| D | AA | 0.356 ± 0.071 | 0.304 ± 0.067 | 0.277 ± 0.047 | 0.300 ± 0.049 | |
| PL | 0.319 ± 0.039 | 0.307 ± 0.043 | 0.300 ± 0.071 | 0.301 ± 0.052 | ||
| Movement time | A | AA | 0.269 ± 0.043 | 0.250 ± 0.033 | 0.246 ± 0.030 | 0.258 ± 0.042 |
| PL | 0.263 ± 0.033 | 0.260 ± 0.042 | 0.273 ± 0.039 | 0.262 ± 0.040 | ||
| B | AA | 0.278 ± 0.041 | 0.266 ± 0.035 | 0.262 ± 0.032 | 0.263 ± 0.030 | |
| PL | 0.279 ± 0.033 | 0.294 ± 0.071 | 0.275 ± 0.033 | 0.272 ± 0.032 | ||
| C | AA | 0.270 ± 0.050 | 0.269 ± 0.037 | 0.264 ± 0.028 | 0.243 ± 0.066 | |
| PL | 0.282 ± 0.036 | 0.277 ± 0.044 | 0.276 ± 0.032 | 0.281 ± 0.035 | ||
| D | AA | 0.272 ± 0.038 | 0.272 ± 0.030 | 0.260 ± 0.032 | 0.269 ± 0.032 | |
| PL | 0.267 ± 0.069 | 0.274 ± 0.051 | 0.280 ± 0.034 | 0.278 ± 0.041 |
aMovement A: a roundhouse kick to the rib; Movement B: a roundhouse kick to the rib, a roundhouse kick to the head, then a reverse roundhouse kick to the head; Movement C: a roundhouse kick to the rib, a roundhouse kick to the head, a reverse roundhouse kick to the head, a roundhouse kick to the head, a reverse roundhouse kick to the head, then a roundhouse kick to the head; Movement D: the primary task in a dual-task setting, same as Movement C. b AA BCAA, arginine, and citruline, PL placebo
Fig. 3Plasma BCAA (a) and tryptophan (b) concentrations and tryptophan/BCAA ratio (c) in the AA and PL trialsa. aAA: BCAA, arginine, and citrulline; PL: placebo. (a) Main effects: trial: p < .001; time: p < .001; interaction: p < .001; (b) Main effects: trial: p = .252;time: p = .050; interaction: p = .196; (c) Main effects: trial: p < .001;time: p < .001; interaction: p < .001; *Significantly different between the 2 trials (p < .001). † Significantly different from the baseline in the AA trial (p < .05)
Fig. 4Plasma NH3 (a) and NOx (b) concentrations in the AA and PL trialsa. aAA: BCAA, arginine, and citrulline; PL: placebo. (a) Main effects: trial: p = .289;time: p < .001; interaction: p = .958; (b) Main effects: trial: p = .252; time: p = .050; interaction: p = .196. *Significantly different between the 2 trials (p < .05). †Significantly different from the baseline in the AA trial (p < .05). #Significantly different from the baseline in the PL trial (p < .05)
Plasma biochemical parameters and ratings of perceived exertions in the AA and PL trials
| Triala | Baseline | post-M1 | post-M2 | pre-M2 | post-M3 | |
|---|---|---|---|---|---|---|
| Urea (mM)1 | AA | 4.61 ± 1.72 | 8.20 ± 3.65 | 12.70 ± 4.50* | 13.25 ± 4.10* | 17.56 ± 5.30* |
| PL | 4.55 ± 1.90 | 7.36 ± 2.30 | 12.95 ± 5.00* | 9.07 ± 4.00 | 16.92 ± 5.10* | |
| Lactate (mM)2 | AA | 2.95 ± 0.77 | 13.38 ± 4.17* | 12.78 ± 3.77 | 2.22 ± 0.53 | 11.93 ± 2.90 |
| PL | 3.19 ± 0.75 | 13.37 ± 2.96* | 12.24 ± 3.45 | 2.36 ± 0.55 | 12.57 ± 2.27 | |
| Glucose (mM)3 | AA | 5.26 ± 0.28 | 4.39 ± 0.44* | 4.97 ± 0.50 | 5.37 ± 0.39 | 5.12 ± 0.50 |
| PL | 5.25 ± 0.44 | 4.20 ± 0.27* | 4.89 ± 0.39 | 5.36 ± 0.22 | 5.28 ± 0.39 | |
| Glycerol (μM)4 | AA | 27.75 ± 10.37 | 49.38 ± 22.00 | 76.48 ± 27.14* | 79.81 ± 24.91* | 105.78 ± 31.76* |
| PL | 27.42 ± 11.39 | 44.34 ± 13.96 | 78.00 ± 30.22* | 54.65 ± 24.31 | 101.91 ± 30.93* | |
| NEFA (mM)b,5 | AA | 0.33 ± 0.17 | 0.21 ± 0.08 | 0.34 ± 0.15 | 0.38 ± 0.12 | 0.47 ± 0.20 |
| PL | 0.36 ± 0.16 | 0.21 ± 0.06 | 0.38 ± 0.10 | 0.58 ± 0.24 | 0.55 ± 0.19 | |
| RPEc,6 | AA | 9.3 ± 2.0 | 16.0 ± 2.0* | 15.9 ± 2.0* | - | 15.2 ± 3.0* |
| PL | 9.3 ± 2.0 | 12.8 ± 2.0* | 13.6 ± 2.0* | - | 14.6 ± 2.0* |
a AA BCAA, arginine, and citruline, PL placebo. b NEFA non-esterified fatty acid. c RPE ratings of perceived exertion. *Significantly different from baseline in the same trial (p < .05)
1Main effects: trial: p = .329; time: p < .001; interaction: p = .167
2Main effects: trial: p = .325; time: p < .001; interaction: p = .165
3Main effects: trial: p = .816; time: p < .001; interaction: p = .520
4Main effects: trial: p = .325; time: p < .001; interaction: p = .165
5Main effects: trial: p = .117; time: p < .001; interaction: p = .213
6Main effects: trial: p = .886; time: p = .003; interaction: p = .718